Menu

Study Finds Inaccuracies in 40 Percent of DTC Genetic Testing Results

An analysis of 49 patient samples finds high proportions of false positives and misinterpretation.

Mar 28, 2018
Shawna Williams

ISTOCK, STEVANOVICIGORA small study of direct-to-consumer (DTC) genetic tests, conducted by clinical diagnostics company Ambry Genetics, found that 40 percent of the variants identified were false positives. The authors of the study, which appears today (March 28) in Genetics in Medicine, also note that among the variants that had been flagged as bringing increased risk of disease—either by the DTC testing companies or third-party interpretation services—eight were in fact benign.

“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing methods may explain some of the differences between Ambry’s results and those of the DTC testing companies.

Companies such as 23andMe and ancestry.com offer consumers what are sometimes known as recreational tests, typically through the mail, with no need to go through a doctor or genetic counselor. While the summary of results may include information on ancestry or traits such earwax consistency, the authors of the study note that the US Food and Drug Administration prohibits most DTC testing companies from providing results with medical implications. However, some companies do offer raw testing data, which people can have interpreted by a third-party service.

The research team analyzed the results of 49 patients whose records indicated they sought confirmatory testing through a medical provider after receiving worrying results. Of the 40 percent of gene variant testing results that Ambry did not confirm, almost all (16/17) were linked to cancer susceptibility, and one was for a connective tissue disorder. 

“No test is accurate every time you run it,” genetic counselor and president of the National Society for Genetic Counselors Erica Ramos tells Lifehacker. Ramos works for Illumina, which partially owns DTC testing service Helix.

“Genetic testing needs to be interpreted by a qualified health-care professional in the context of several other factors, such as personal and family medical history,” the authors of the study conclude. “It is our hope that confirmatory testing and appropriate clinical management by all health-care professionals accompany DTC genetic testing for at-risk patients.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.